Changes in Beneficial Ownership · 4
Tvardi Therapeutics, Inc.
TVRDNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-06112026_040613.xml
Filing details
- Report period
- 2026-06-09
- Issuer
- Tvardi Therapeutics, Inc.
- Issuer CIK
- 0001346830
- Trading symbol
- TVRD
Reporting owner 1
- Name
- WYZGA MICHAEL S
- Reporting owner CIK
- 0001201256
- Relationship
- Director
- Address
- C/O TVARDI THERAPEUTICS, INC., 3 SUGAR CREEK CTR BLVD, STE 525, SUGAR LAND, TX, 77478
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 2.78 | 2026-06-09 | A · Form 4 | 6,000 | A | 0 | [F1] | 2036-06-08 | Common Stock | 6,000 | 6,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.↩ 1
Signature 1
- Signed
- /s/ Dan Conn, Attorney-in-Fact
- Date
- 2026-06-11
Company context
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company is conducting clinical trials with TTI-109 in healthy volunteers and TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).